Simultaneous quantitation of methotrexate and its two main metabolites in biological fluids by a novel solid-phase extraction procedure using high-performance liquid chromatography.
We have developed an assay for the simultaneous determination of methotrexate (MTX) and its main metabolites, 7-hydroxymethotrexate (7-OHMTX) and 2,4-diamino-N10-methylpteroic acid (DAMPA) in plasma, urine and saliva meeting the requirement of rapidity for routine use in high-dose MTX therapy and the requirement of sensitivity for its potential use in therapeutic drug monitoring in low-dose MTX therapy. Sample preparation is based on solid-phase extraction using C8 Isolute cartridges. Chromatographic separation was achieved with a reversed-phase column (C18), and quantitation by subsequent exposure to UV light of 254 nm, which converted MTX and its two metabolites by photolytic oxidation to fluorescent products. The recoveries of MTX, 7-OHMTX and DAMPA from plasma at 100 nmol/l were 85.8, 91.1 and 102.3%, respectively. The limits of detection for MTX, 7-OHMTX and DAMPA in plasma and saliva were 0.1 nmol/l. In urine the limit of detection was 10 nmol/l for all compounds. The limits of quantitation in plasma and saliva were 0.5 nmol/l for all compounds.
Albertioni
F
F
Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden.
Pettersson
B
B
Beck
O
O
Rask
C
C
Seideman
P
P
Peterson
C
C
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D008727:Methotrexate / Q000032:analysis* / Q000097:blood / Q000652:urine; D015203:Reproducibility of Results; D012463:Saliva / Q000378:metabolism; D013050:Spectrometry, Fluorescence
D008727:Methotrexate